Guidelines for the diagnosis and management of Catecholaminergic Polymorphic Ventricular Tachycardia

Heart Lung and Circulation

Volumn 21, Issue 2, 2012, Pages 96-100

  Pflaumer, Andreas ^a,b   Davis, Andrew M ^a,b,c  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

Author keywords

Bidirectional ventricular tachycardia; Calsequestrin; Catecholaminergic polymorphic ventricular tachycardia; CPVT; Diagnosis; Genetics; Guidelines; Management; Ryanodine; Sudden death

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM ION; FLECAINIDE; VERAPAMIL;

ARTICLE; CALCIUM TRANSPORT; CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA; CLINICAL FEATURE; DEFIBRILLATION; DEFIBRILLATOR; DENERVATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; ELECTROCARDIOGRAM; EMOTIONAL STRESS; EXERCISE; EXERCISE TEST; FAMILY HISTORY; GENE MUTATION; GENETIC ANALYSIS; GENETIC COUNSELING; HEART ARREST; HIGH RISK POPULATION; HOLTER MONITORING; HUMAN; MOLECULAR GENETICS; NEUROSURGERY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECEPTOR GENE; RELATIVE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RYANODINE RECEPTOR 2 GENE; SYNCOPE; TREATMENT INDICATION;

ADRENERGIC BETA-ANTAGONISTS; DEFIBRILLATORS, IMPLANTABLE; DIAGNOSIS, DIFFERENTIAL; DNA; ELECTROCARDIOGRAPHY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; PRACTICE GUIDELINES AS TOPIC; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; TACHYCARDIA, VENTRICULAR;

EID: 84856336999     PISSN: 14439506     EISSN: 14442892     Source Type: Journal    
DOI: 10.1016/j.hlc.2011.10.008     Document Type: Article

References (18)

1. Priori S.G., Napolitano C., Memmi M., Colombi B., Drago F., Gasparini M., et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation 2002, 106:69-74.
2. Leenhardt A., Lucet V., Denjoy I., Grau F., Ngoc D.D., Coumel P. Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients. Circulation 1995, 91:1512-1519.
3. Fisher J.D., Krikler D., Hallidie-Smith K.A. Familial polymorphic ventricular arrhythmias: a quarter century of successful medical treatment based on serial exercise-pharmacologic testing. J Am Coll Cardiol 1999, 34:2015-2022.
4. Liu N., Rizzi N., Boveri L., Priori S.G. Ryanodine receptor and calsequestrin in arrhythmogenesis: what we have learnt from genetic diseases and transgenic mice. J Mol Cell Cardiol 2009, 46:149-159.
5. Maron B.J., Chaitman B.R., Ackerman M.J., Bayés de Luna A., Corrado D., Crosson J.E., et al. Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation 2004, 109:2807-2816.
6. Hayashi M., Denjoy I., Extramiana F., Maltret A., Buisson N.R., Lupoglazoff J., et al. Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia. Circulation 2009, 119:2426-2434.
7. Zipes D.P., Camm A.J., Borggrefe M., Buxton A.E., Chaitman B., Fromer M., et al. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006, 114:e385-e484.
8. Rosso R., Kalman J.M., Rogowski O., Diamant S., Birger A., Biner S., et al. Calcium channel blockers and beta-blockers versus beta-blockers alone for preventing exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm 2007, 4:1149-1154.
9. Swan H., Laitinen P., Kontula K., Toivonen L. Calcium channel antagonism reduces exercise-induced ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia patients with RyR2 mutations. J Cardiovasc Electrophysiol 2005, 16:162-166.
10. Watanabe H., Chopra N., Laver D., Hwang H.S., Davies S.S., Roach D.E., et al. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med 2009, 15:380-383.
11. van der Werf C., Kannankeril P.J., Sacher F., Viskin S., Leenhardt A., et al. Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. J Am Coll Cardiol 2011, 57:2244-2254.
12. Pizzale S., Gollob M.H., Gow R., Birnie D.H. Sudden death in a young man with catecholaminergic polymorphic ventricular tachycardia and paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol 2008, 19:1319-1321.
13. Mohamed U., Gollob M.H., Gow R.M., Krahn A.D. Sudden cardiac death despite an implantable cardioverter-defibrillator in a young female with catecholaminergic ventricular tachycardia. Heart Rhythm 2006, 3:1486-1489.
14. Collura C.A., Johnson J.N., Moir C., Ackerman M.J. Left cardiac sympathetic denervation for the treatment of long QT syndrome and catecholaminergic polymorphic ventricular tachycardia using video-assisted thoracic surgery. Heart Rhythm 2009, 6:752-759.
15. Atallah J., Fynn-Thompson F., Cecchin F., DiBardino D.J., Walsh E.P., Berul C.I. Video-assisted thoracoscopic cardiac denervation: a potential novel therapeutic option for children with intractable ventricular arrhythmias. Ann Thorac Surg 2008, 86:1620-1625.
16. Wilde A.A., Bhuiyan Z.A., Crotti L., Facchini M., De Ferrari G.M., Paul T., et al. Left cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachycardia. New Engl J Med 2008, 358:2024-2029.
17. di Barletta M.R., Viatchenko-Karpinski S., Nori A., Memmi M., Terentyev D., Turcato F., et al. Clinical phenotype and functional characterization of CASQ2 mutations associated with catecholaminergic polymorphic ventricular tachycardia. Circulation 2006, 114:1012-1019.
18. Haugaa K.H., Leren I.S., Berge K.E., Loennechen J.P., Anfinsen O.-G., et al. High prevalence of exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia mutation-positive family members diagnosed by cascade genetic screening. Europace 2010, 12:417-423.